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Disseminated aspergillosis is responsible for a high mortality rate, despite the use of anti-
fungal drugs. Adjuvant therapies are urgently needed to improve the outcome. The aim of
this study was to demonstrate that the cytoprotective effect of erythropoietin (EPO) com-
bined with amphotericin B can reduce the mortality rate in a murine model of disseminated
aspergillosis. After infection with Aspergillus fumigatus, neutropenic mice were random-
ized to receive vehicle or 7.5 mg/kg liposomal amphotericin B (LAmB) or 7.5 mg/kg LAmB
combined with 1000 IU/kg EPO (16 mice per group). Aspergillus galactomannan and organ
cultures were performed to evaluate fungal burden at day 5. Cumulative long-term survival
was analyzed at day 12 post-infection according to the Kaplan–Meier method. At day 5,
fungal burden was similar between non-treated and treated groups. At day 12, mortal-
ity rates were 75, 62.5, and 31% in control group, LAmB group, and EPO/LAmB group,
respectively. We observed a significant decrease in mortality using EPO/LAmB combina-
tion compared to control group (p<0.01). LAmB single treatment did not improve the
survival rate compared to control group (p=0.155). Our results provide the first evidence
that EPO improved the outcome of mice presenting with disseminated aspergillosis when
combined with amphotericin B.
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INTRODUCTION
Aspergillus fumigatus is a ubiquitous and opportunistic fungi,
responsible for disseminated infections in immunocompromised
patients including hematopoietic stem cell transplant, solid organ
transplant recipients, and patients receiving immunosuppressive
drugs (1). Invasive aspergillosis (IA) is the second most frequent
invasive fungal infection in neutropenic patients (2) leading to a
high mortality rate, despite the use of last generation antifungals
(3). IA has a huge clinical and economical burden, and remains
one of the worst fears of clinicians treating high-risk patients.
While new antifungals have been developed and widely used to
treat this disease, there is evidence that the outcome is highly
associated with the time of treatment induction. Any delay in diag-
nosis and treatment decreases the rate of favorable outcome (4).
Since clinical, radiological, and biological diagnoses are difficult
and require time consuming investigations, it could be supposed
that any additional treatment that postponed the dissemination
of the fungus from the lung could help to improve the outcome.
Recent research have recently focused on targeting virulence as a
new paradigm for antifungals (5); virulence factors, such as pro-
teases, phospholipases, catalases, and calcineurin, used by yeast
and molds, are potential targets to improve fungal treatments (5).
A. fumigatus growing in the respiratory tract is responsible for
epithelial and endothelial cells injuries, disruption of the blood
vessels integrity leading to hemorrhages and fungemia (6, 7). The
translocation of the fungi from the respiratory tract to the blood
is responsible for IA in immunosuppressed patients (8, 9). We
wondered whether the concept of cell protective therapy in com-
bination with antifungals may help to improve the outcome of
disseminated aspergillosis for high-risk patients at an early stage of
this disease. Among the potential cell protective drugs, erythropoi-
etin (EPO) is one of the most promising drug due to its capacity
to prevent programed cell death, to reduce the development of
pro-inflammatory cytokine, and to enable tissue regeneration (10,
11). Recent studies demonstrated the beneficial effect of EPO or
EPO analogs after acute lung injury (12) or during sepsis (13,
14). In order to document our hypothesis, we set up a murine
model of disseminated aspergillosis and we studied the effect on
the mortality rate of a combination of EPO high doses associated
to amphotericin B.
MATERIALS AND METHODS
MICE, FUNGUS, AND INFECTION
Animal experiments were conducted according to the Institu-
tional Animal Care and Use Committee guidelines of University
Claude Bernard Lyon 1 (approved protocol No. BH2012-07).
CBA/J female mice 6 weeks old (Janvier, France) were immuno-
suppressed at day 0 using intraperitoneal injection of cylophos-
phamide (250 mg/kg) (Baxter, France). This immunosuppressive
treatment induced severe neutropenia (<0.01 G/L) from day 3 to
5. Mice were infected intraperitoneally at day 3 with 107 coni-
dia of A. fumigatus ATCC 13073 (LGC Standards, France). In
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our experiments, our objectives were not to reproduce the way
of infection, but to measure the effect of a drug on the invasive-
ness of Aspergillus at an early stage of the disease. Intraperitoneal
infection is a simple way of infection allowing the dissemination
of Aspergillus, as described for other pathogens, including Toxo-
plasma gondii (15), Influenza A virus (16), or Ehrlichia muris-like
agent (17).
TREATMENTS
After immunosuppression and infection, mice were randomly sep-
arated in three groups (16 mice per group). Based on observation
in human beings (18), we calibrated the dose of liposomal ampho-
tericin B (LAmB) (AMBISOME®, Gilead, Boulogne, France) at
7.5 mg/kg/day to cure 40% of mice, a success rate similar to
human treatment. EPO was used at 1000 IU/kg/day, as previously
described in a murine model of cerebral malaria (19, 20) and a
clinical trial in human beings (21). (Group 1 (control) received
the vehicle of drugs (glucose 5%) from day 4 to 7. Group 2
(LAmB) received LAmB (7.5 mg/kg/day) from day 4 to 7. Group
3 (LAmB/EPO) received a combination of LAmB (7.5 mg/kg/day)
and EPO (1000 IU/kg/day) (epoietin beta, NEORECORMON®,
Roche, Levallois-Perret, France) from day 4 to 7. Experiments were
repeated twice.
INVASIVE ASPERGILLOSIS
To confirm that the same fungal burden was reached in each group,
hearts, lungs, livers, and brains were collected from mice dead at
day 5 (Group 1: n= 10; Group 2: n= 3; Group 3: n= 3). Two stan-
dardized fragments of each organ were sampled. One was used
for culture on Sabouraud agar at 37°C during 7 days. The second
was grinded in saline and after centrifugation, Platelia Aspergillus
galactomannan EIA (Bio-Rad, Marnes-la-Coquette, France) was
performed on the supernatant.
STATISTICAL ANALYSIS
Cumulative long-term survival was calculated according to the
Kaplan–Meier method and groups were compared with the log
rank test using SPSS 20.0 (LEAD Technologies, Chicago, USA).
Survival time was the dependant variable. p-value of <0.05 was
considered significant.
RESULTS
INVASIVE ASPERGILLOSIS
Intraperitoneal infection led to a reproducible disseminated
aspergillosis at day 5, as demonstrated by Aspergillus cul-
ture positives for all organs tested and by the galactomannan
antigen index (positive threshold= 1) in extracts from hearts
(9.3± 1.8), lungs (10.3± 0.1), livers (10.1± 0.1), and brains
(4.1± 2.5).
At day 5, there was no difference (student t -test, p> 0.1) in
fungal burden between non-treated and treated groups (galac-
tomannan index means were 8.5± 1.1, 9.0± 0.5, and 8.4± 0.8 for
untreated, LAmB treated, and LAmB/EPO treated mice, respec-
tively). The galactomannan levels are also similar (student t -
test, p> 0.1) between groups if organs are considered (heart:
9.3± 1.8, 10.3± 0.4, and 9.8± 1.3; lungs: 10.3± 0.1, 10.3± 0.3,
and 10.5± 0.2; livers: 10.1± 0.1, 10.4± 0.3, and 10.3± 0.2; brains:
4.1± 2.5, 5.1± 1.1, and 3.0± 1.3 for untreated, LAmB treated, and
LAmB/EPO treated mice groups, respectively).
INCREASED SURVIVAL RATE WHEN EPO IS COMBINED WITH AMB
TREATMENT
Mortality rates at day 12 were 75, 62.5, and 31% in control group,
LAmB group, and LAmB/EPO group, respectively (Figure 1). As
expected, LAmB did not significantly improve the survival rate
compared to control group (p= 0.155), in agreement with the
disease severity associated with confirmed IA. Combination of
EPO to LAmB led to a slight reduction in mortality rate compared
to LAmB (p= 0.07). More interestingly, we observed a significant
decreased mortality using LAmB/EPO combination compared to
control (p< 0.01). In LAmB/EPO treated group, Aspergillus dis-
semination was limited, as demonstrated by the reduction of
fungal burden in lungs (from 33% of mice presenting infected
lung in LAmB group to 0% in LAmB/EPO group). This is the first
evidence for an adjuvant effect of EPO combined to LAmB during
experimental disseminated aspergillosis.
DISCUSSION
While new antifungal drugs are widely used, disseminated
aspergillosis is still associated with an unacceptable mortality rate.
During neutropenia, angioinvasivness of Aspergillus can occur,
resulting in death, despite appropriate antifungal treatment (22).
The poor outcome of disseminated aspergillosis, as well as the
increasing interest for EPO as a cytoprotective drug (23), paved
the way for EPO combination with antifungals when a salvage
therapy is required. In this situation, the antifungal commonly
used as a second-line therapy for IA is LAmB (24).
Considering the need for a proof of concept study before
translation to human beings, we developed a murine model of
disseminated aspergillosis.
The first step was to obtain a disseminated infection after
intraperitoneal inoculation of Aspergillus conidia, to avoid the pul-
monary disease which could lead to death before dissemination.
Intraperitoneal injection of pathogens with a potential to dissem-
inate via blood route are widely used to reproduce disseminated
diseases, including malaria (25), toxoplasmosis (15), erlichiosis
(17), or influenza (16). Many different models of IA have been
developed in the past and recently reviewed in Ref. (26). There
is evidence that none of the animal model perfectly reproduces
the human disease (26). The intraperitoneal infection of mice by
Aspergillus has the advantage to lead to a hematogenous spread
and to avoid the lung tropism of Aspergillus. After immunosup-
pression using cyclophosphamide, we observed a dissemination
of A. fumigatus in heart, lung, liver, and brain, demonstrating
the systemic involvement leading to a high mortality rate of 75%
5 days after infection. While limitations are obvious, our model of
immunosuppressed CBA/J mice infected via intraperitoneal route
is adapted to the study of Aspergillus dissemination.
We calibrated the infection in order to obtain a mortality rate
of 75% at day 8 and the dose of LAmB to reduce mortality rate
to approximately 60%, mimicking the human situation. This high
mortality rate, despite the use of high doses of LAmB, is relevant to
clinical observations in human beings (AmBiLoad trial) (18). The
LAmB/EPO drug combination decreased by half the mortality rate
(31%), demonstrating a significant effect on survival compared to
control (p< 0.01).
Few years ago, antioxidative property of N -acetyl-cystein was
used in mice, in association with amphotericin B, to reduce
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FIGURE 1 | Cumulative survival analysis of the treated and untreated
mice. Control (solid line): mice received the vehicle of drugs (glucose 5%)
from day 4 to 7; LAmB (dotted line): mice received liposomal amphotericin
B (7.5 mg/kg/day) from day 4 to 7; and LAmB/EPO (dash dotted line): mice
received a combination of liposomal amphotericin B (7.5 mg/kg/day) and
recombinant human erythropoietin (1000 IU/kg/day) from day 4 to 7; *p<0.01
for control vs LAmB/EPO and p=0.07 for LAmB vs LAmB/EPO, **p=0.155
for control vs LAmB (Kaplan–Meier analysis, log rank test).
oxidative stress after intratechal infection by Aspergillus (27).
This study showed a positive effect of the combined treat-
ment at the pulmonary tissue level, but the effect on mice
survival was not showed. To our knowledge, we report the
first evidence of a successful combination of a cytoprotec-
tive drug with an antifungal during disseminated aspergillo-
sis.
Aspergillus hyphae damage endothelial cells leading to dis-
ruption of endothelial cell monolayer and dissemination of the
fungus. Interestingly, when EPO was combined to LAmB, the per-
centage of disseminated infection was reduced from 33% in LAmB
treated mice compared to 0% in LAmB/EPO treated mice. This
could be related to the ability of EPO to reduce endothelial perme-
ability as recently demonstrated during intracerebral hemorrhages
(28) and acute lung injury (12).
This hypothesis needs to be confirmed by histopathological
studies. Further studies are also needed to confirm the safety
of short-term regimen of EPO high doses. EPO is suspected
to be responsible for two major side effects: tumor progres-
sion and thromboembolic events (29). The 8 weeks treatment
with epoietin beta (300 UI/kg three times weekly) was associated
with progression of the disease in patients with head and neck
carcinomas (30). In patients with heart disease, long-term treat-
ments with erythropoiesis-stimulating agents were associated with
thromboembolic adverse events (31). In a meta-analysis aimed
at evaluating the impact of epoietin beta on tumor progression
and thromboembolic events, the authors concluded that these
side effects were observed only if baseline hemoglobin values
were increased (29). Since we used 1000 IU/kg/day EPO dur-
ing 4 days, these side effects would be avoided as demonstrated
by Ehrenreich et al. (32). In this safety study, patients received
after ischemic stroke 3 days of intravenous high doses epoietin
beta (33,000 IU/day). The hematocrit, hemoglobin, and red blood
cell counts remained stable throughout the 30-day observation
period (32).
In our hands, we have demonstrated the favorable effect of EPO
on outcome during murine disseminated aspergillosis. Consider-
ing the low risk of side effects using short-term EPO treatment,
clinical trials are urgently needed.
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